{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059093","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.070230+00:00","generated_at":"2026-06-02T01:04:07.465243+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pyxis Oncology Q1 net loss narrows to $3.3M; PYX-201 data on track for fall 2024","bullets":["Revenue of $16.1M from Novartis royalty settlement; net loss $3.3M ($0.06/sh) vs $19.2M ($0.54/sh) YoY.","Cash & investments $158.5M; runway into 2H 2026; raised ~$60.8M via ATM, private placement, and Novartis deal.","PYX-201 Phase 1: 42 patients dosed; 16 more planned; results including efficacy expected fall 2024.","PYX-106 Phase 1: 24 subjects dosed; preliminary data anticipated in 2H 2024.","Appointed Stephen Worsley as Senior Vice President, Chief Business Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059093","json":"https://secwatch.observer/filing/0000950170-24-059093.json","markdown":"https://secwatch.observer/filing/0000950170-24-059093.md","text":"https://secwatch.observer/filing/0000950170-24-059093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024059093/0000950170-24-059093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024059093/pyxs-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:04:07.465243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef5771414ffb271c10574f8326b768d7b0116911","claim":"Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024059093/0000950170-24-059093-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}